United Capital Management of KS’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

United Capital Management of KS’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18,525	Closed	-$29K	–	89
2022 Q3	$29K	Sell	18,525 -4,490	-20%	-$10.2K	0.01%	82
2022 Q2	$46K	Sell	23,015 -6,375	-22%	-$11K	0.02%	81
2022 Q1	$68K	Buy	29,390 +400	+1%	+$1.25K	0.03%	89
2021 Q4	$135K	Buy	28,990 +2,000	+7%	+$12.4K	0.05%	89
2021 Q3	$206K	Buy	26,990 +6,025	+29%	+$51.1K	0.08%	90
2021 Q2	$203K	Buy	+20,965	New	+$167K	0.08%	94

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

United Capital Management of KS's SRNE Position: Q4 2022 in Review

United Capital Management of KS sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 18,525 shares — an estimated $29K sold.

United Capital Management of KS first reported a position in SRNE in Q2 2021 and held it in 6 quarters. The position peaked at $206K in Q3 2021. 223 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

United Capital Management of KS reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
United Capital Management of KS sold 18,525 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $29K.
United Capital Management of KS first reported a position in Sorrento Therapeutics, Inc. in Q2 2021 and held it in 6 quarters.
United Capital Management of KS's Sorrento Therapeutics, Inc. position peaked at $206K in Q3 2021.
223 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on United Capital Management of KS's 13F filing for Q4 2022, filed 31 Jan 2023.